Testing a new drug combo for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (QL1706 and lenvatinib) for people with advanced esophageal cancer that has stopped responding to standard immunotherapy. The goal is to see if this new treatment can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced esophageal squamous cell carcinoma that cannot be removed with surgery.
- Your cancer must have gotten worse after standard immunotherapy with drugs like Keytruda or Opdivo.
- You must have at least one tumor that can be measured on a scan.
- You must be able to take care of yourself (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug called QL1706 to standard chemotherapy (two common cancer drugs) works better for advanced esophageal cancer that can't be surgically removed. The goal is to see if this combination helps patients live longer and controls the cancer better than chemotherapy alone.
This study tests a new treatment approach for patients with advanced esophageal cancer whose disease progressed or didn't respond to initial chemotherapy and immunotherapy. The goal is to see if this new treatment can help shrink tumors and improve outcomes for patients who cannot have surgery.
This trial tests an experimental drug (PD-1/IL-2α-bias bispecific antibody fusion protein) for people with advanced esophageal squamous cell cancer that has gotten worse after prior immunotherapy and chemotherapy. The goal is to see if this treatment can help when other options have stopped working.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
This trial tests a combination of two drugs, QL1706 and celecoxib, in people with advanced esophageal cancer that has worsened after prior immunotherapy. The goal is to see if this new combination can help shrink tumors or slow disease progression.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.